Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 129

Sort by

Sort Order Select

Journal Articles

Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies

David H. Quach, Premal Lulla, Cliona M. Rooney

Blood (2023) 141 (8): 877–885.

https://doi.org/10.1182/blood.2022016202

Published: 2023

Journal Articles

LigandCD70.CAR As a Platform for Dual-Targeting CAR T Cells for Acute Myeloid Leukemia

Lauren Scherer, Candise Tat, Tim Sauer, Haruko Tashiro, Swati Naik, Mireya Paulina Velasquez, Stephen Gottschalk, Cliona M. Rooney, Malcolm K. Brenner, Bilal Omer

Blood (2022) 140 (Supplement 1): 7396–7397.

https://doi.org/10.1182/blood-2022-170503

Published: 2022

Journal Articles

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Blood (2022) 140 (Supplement 1): 412–414.

https://doi.org/10.1182/blood-2022-160244

Published: 2022

Journal Articles

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Blood (2022) 140 (1): 16–24.

https://doi.org/10.1182/blood.2022015728

Published: 2022

Journal Articles

Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL

Blood (2022) 139 (17): 2706–2711.

https://doi.org/10.1182/blood.2021014648

Published: 2022

Includes: Supplemental data

Journal Articles

Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL

Blood (2021) 138 (Supplement 1): 471.

https://doi.org/10.1182/blood-2021-149332

Published: 2021

Journal Articles

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Blood (2021) 138 (Supplement 1): 1763.

https://doi.org/10.1182/blood-2021-153421

Published: 2021

Journal Articles

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

Tim Sauer, Kathan Parikh, Sandhya Sharma, Bilal Omer, David Sedloev, Qian Chen, Linus Angenendt, Christoph Schliemann, Michael Schmitt, Carsten Müller-Tidow, Stephen Gottschalk, Cliona M. Rooney

Blood (2021) 138 (4): 318–330.

https://doi.org/10.1182/blood.2020008221

Published: 2021

Includes: Supplemental data

Journal Articles

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

David H. Quach, PhD, Haran R. Ganesh, BS, Sachin Thakkar, PhD, Luis Becerra-Dominguez, BS, Birju Mehta, MS, Silvana Perconti, MS, Eric Anderson, BS, Emily M. Hsieh, MD, Olga Dakhova, MD, Huimin Zhang, BS, Bambi J. Grilley, RPh, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD DSc, Carlos A. Ramos, MD, Rayne H. Rouce, MD, Natalia Lapteva, PhD, Cliona M. Rooney, PhD

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-141491

Published: 2020

Journal Articles

CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia (AML) without HSC Toxicity

Tim Sauer, MD, Kathan Parikh, Sandhya Sharma, Bilal Omer, MD, Stephen Gottschalk, MD, Cliona M. Rooney, PhD

Blood (2019) 134 (Supplement_1): 1932.

https://doi.org/10.1182/blood-2019-125534

Published: 2019

Journal Articles

CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)

Carlos A. Ramos, MD, Mrinalini Bilgi, Claudia P. Gerken, Olga Dakhova, Zhuyong Mei, Bambi J. Grilley, RPh, Adrian P. Gee, PhD, Cliona M. Rooney, PhD, Gianpietro Dotti, MD, Barbara Savoldo, MD PhD, Helen E. Heslop, MDDSc, Malcolm K. Brenner, MD PhD

Blood (2018) 132 (Supplement 1): 680.

https://doi.org/10.1182/blood-2018-99-111202

Published: 2018

Journal Articles

Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells

George Carrum, MD, Premal Lulla, MBBS, Ifigeneia Tzannou, MD, Ayumi Watanabe, Manik Kuvalekar, Mrinalini Bilgi, Rammurti Kamble, MD, Carlos A. Ramos, MD, Rayne Rouce, MD, Bambi J. Grilley, RPh, Adrian P. Gee, PhD, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MDDSc, Cliona M. Rooney, PhD, Juan F. Vera, MD, Ann M. Leen, PhD

Blood (2018) 132 (Supplement 1): 1685.

https://doi.org/10.1182/blood-2018-99-113140

Published: 2018

Journal Articles

EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation

Lauren P. McLaughlin, Rayne Rouce, Stephen Gottschalk, Vicky Torrano, George Carrum, Meng-Fen Wu, Fahmida Hoq, Bambi Grilley, Andrea M. Marcogliese, Patrick J. Hanley, Adrian P. Gee, Malcolm K. Brenner, Cliona M. Rooney, Helen E. Heslop, Catherine M. Bollard

Blood (2018) 132 (22): 2351–2361.

https://doi.org/10.1182/blood-2018-07-863654

Published: 2018

Journal Articles

Autologous EBV-Specific T Cells (CMD-003): Early Results from a Multicenter, Multinational Phase 2 Trial for Treatment of EBV-Associated NK/T-Cell Lymphoma

Blood (2017) 130 (Supplement 1): 4073.

https://doi.org/10.1182/blood.V130.Suppl_1.4073.4073

Published: 2017

Journal Articles

Adoptive Immunotherapy with Rapidly-Generated Multivirus-Specific T Cells Against AdV, EBV, CMV, HHV6 and BK after Allogeneic Hematopoietic Stem Cell Transplant

Blood (2017) 130 (Supplement 1): 4484.

https://doi.org/10.1182/blood.V130.Suppl_1.4484.4484

Published: 2017

Journal Articles

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Michael Boyiadzis, MD MHSc, Mounzer Agha, MD, Robert L Redner, MD, Alison Sehgal, MD, Annie Im, MD, Jing-Zhou Hou, Rafic Farah, MD, Kathleen A. Dorritie, MD, Anastasios Raptis, MD PhD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Hans Klingemann, MD PhD, Hong Wang, PhD, Natalia Lapteva, PhD, Mei Zhuyong, MD, Lisa H Butterfield, PhD, Cliona M. Rooney, PhD, Theresa L Whiteside, PhD

Blood (2016) 128 (22): 1649.

https://doi.org/10.1182/blood.V128.22.1649.1649

Published: 2016

Journal Articles

Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant

Ifigeneia Tzannou, MD, Anastasia Papadopoulou, PhD, Ayumi Watanabe, Manik Kuvalekar, Adrian P. Gee, PhD, Swati Naik, MD, Caridad Martinez, MD, Kathryn S. Leung, Ghadir S. Sasa, MD, Robert A. Krance, MD, George Carrum, MD, Carlos A. Ramos, MD, Bambi Grilley, Malcolm K. Brenner, MD PhD, Cliona M. Rooney, PhD, Helen E Heslop, MD DSc (Hon), Ann M. Leen, PhD, Bilal Omer, MD

Blood (2016) 128 (22): 501.

https://doi.org/10.1182/blood.V128.22.501.501

Published: 2016

Journal Articles

CAR T Cells Targeted with a High Affinity Scfv Against the HCMV Glycoprotein Gb As Adoptive T Cell Therapy after Hematopoietic Stem Cell Transplantation

Renata Stripecke, PhD, Laura Gerasch, Sebastian Theobald, Bala Sai Sundarasetty, PhD, Maksim Mamonkin, PhD, Thomas Shum, BS, Cliona M. Rooney, PhD

Blood (2016) 128 (22): 5721.

https://doi.org/10.1182/blood.V128.22.5721.5721

Published: 2016

Journal Articles

Rapidly-Generated EBV-Specific T Cells (EBVST-cells) to Treat Type 2 Latency Lymphoma

Rayne H. Rouce, MD, Birju Mehta, Sandhya Sharma, Serena Kimi Perna, MD, Benjamin Shin, Vicky Torrano, Fnu Spoorthi, Natalia Lapteva, PhD, Catherine M. Bollard, MD, Adrian P. Gee, PhD, Carlos A. Ramos, MD, Shannon Inman, Karen L. Hodgkin, Kurt C. Gunter, MD, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD, Cliona M. Rooney, PhD

Blood (2016) 128 (22): 2990.

https://doi.org/10.1182/blood.V128.22.2990.2990

Published: 2016

Journal Articles

Fast and Efficient Gene Editing in Human Hematopoietic Cells

Michael C Gundry, BS, Lorenzo Brunetti, MD, Dimitrios Laurin Wagner, Joanne Hsu, BS, Mireya Paulina Velasquez, MD, Stephen Gottschalk, MD, Cliona M. Rooney, PhD, Margaret Goodell, PhD

Blood (2016) 128 (22): 4704.

https://doi.org/10.1182/blood.V128.22.4704.4704

Published: 2016

NARROW

Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies

LigandCD70.CAR As a Platform for Dual-Targeting CAR T Cells for Acute Myeloid Leukemia

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL

Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia (AML) without HSC Toxicity

CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)

Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells

EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation

Autologous EBV-Specific T Cells (CMD-003): Early Results from a Multicenter, Multinational Phase 2 Trial for Treatment of EBV-Associated NK/T-Cell Lymphoma

Adoptive Immunotherapy with Rapidly-Generated Multivirus-Specific T Cells Against AdV, EBV, CMV, HHV6 and BK after Allogeneic Hematopoietic Stem Cell Transplant

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant

CAR T Cells Targeted with a High Affinity Scfv Against the HCMV Glycoprotein Gb As Adoptive T Cell Therapy after Hematopoietic Stem Cell Transplantation

Rapidly-Generated EBV-Specific T Cells (EBVST-cells) to Treat Type 2 Latency Lymphoma

Fast and Efficient Gene Editing in Human Hematopoietic Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only